Pfizer Inc. is recalling approximately 26,502 bottles of Quillivant XR (methylphenidate HCl) extended-release oral suspension because the medication failed to meet dissolution specifications during testing. This defect means the drug may not release its active ingredient at the intended rate, which can prevent the patient from receiving the correct therapeutic dose. The recall includes 600 mg/120 mL and 750 mg/150 mL bottles distributed nationwide across the United States. Consumers should contact their healthcare provider to discuss alternative treatment options while returning affected bottles to their place of purchase.
The drug failed dissolution testing, meaning it may not break down properly in the body. This can result in the medication being less effective or providing an inconsistent dose, potentially leading to poorly managed symptoms of the condition being treated.
Contact your healthcare provider or pharmacist for guidance.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.